1-855-378-42281-855-378-4228
One of the outpatient treatment alternatives for people in Eddyville battling with opioid dependence and addiction is called opioid maintenance therapy. Some facilities and doctors are certified to administer certain meds to opioid addicted clients, many of which are opioid-based also and are addiction. With low enough doses however, the client doesn't experience being high and also doesn't experience acute cravings and is not experiencing opioid withdrawal. Methadone is the first med tried for this purpose, but there are alternative options currently to pick from.
Methadone is an opiate and is meant to be taken at an outpatient clinic certified to dispense the drug, that is taken on a daily basis as a pill or liquid. The cost of the drug is around one hundred and fifty dolloars a month. Buprenorphine is also an opioid-based med, and is in pill form often taken one day on, one day off. But unlike Methadone which is only be dispensed in well-regulated clinics, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The price monthly of buprenorphine is about $300.00 /month for the generic of the medication. There is also a version of buprenorphine that contains the ingredient naloxone, which is a med which reverses the effects of opiates. An individual taking this formulation, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It too is taken daily, and is priced approximately $450 monthly. Naltrexone is an additional medication taken in opioid maintenance therapy, but unlike the other drugs aforementioned it's an opioid blocker and is not an opiate. There is an option to take this drug as a monthly shot, which is called Vivitrol. As an opioid blocker, the drug prevents a person from experience high feelings from opioids, and therefore lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 monthly.
For All Alcohol and Drug Treatment Centers In Eddyville, Click Here.
